These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 16842091)
1. Treatment of Alzheimer's disease: the beginning of a new era. Schenk D Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091 [No Abstract] [Full Text] [Related]
2. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models. Busche MA; Grienberger C; Keskin AD; Song B; Neumann U; Staufenbiel M; Förstl H; Konnerth A Nat Neurosci; 2015 Dec; 18(12):1725-7. PubMed ID: 26551546 [TBL] [Abstract][Full Text] [Related]
3. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I. Agadjanyan MG; Cribbs DH CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):1-6. PubMed ID: 19275632 [No Abstract] [Full Text] [Related]
5. [The role of beta-amyloid peptide in pathogenesis and immunotherapy of Alzheimer's diseases]. Yu SN; Liu LY; Liang P Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):113-4. PubMed ID: 15842811 [No Abstract] [Full Text] [Related]
6. Immunotherapy for Alzheimer's disease. Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646 [TBL] [Abstract][Full Text] [Related]
7. Alzheimer disease. Could anti-amyloid-β immunotherapy do more harm than good? Wood H Nat Rev Neurol; 2016 Jan; 12(1):2. PubMed ID: 26610710 [No Abstract] [Full Text] [Related]
8. [Adaptive immunity to Aβ amyloid peptide in Alzheimer's disease: lessons and perspectives]. Dorothée G; Aucouturier P Med Sci (Paris); 2011 Nov; 27(11):938-40. PubMed ID: 22130019 [No Abstract] [Full Text] [Related]
10. [Current status of Alzheimer's disease immunotherapy and pharmacologic effect of BAN2401.]. Araki S Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):21-5. PubMed ID: 20628209 [No Abstract] [Full Text] [Related]
11. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Schenk DB; Seubert P; Grundman M; Black R Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006 [TBL] [Abstract][Full Text] [Related]
12. [Current trend of immunotherapy for Alzheimer's disease]. Matsumoto SE; Tabira T Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765 [TBL] [Abstract][Full Text] [Related]
13. [Development of therapies of Alzheimer's disease]. Shoji M Nihon Ronen Igakkai Zasshi; 2003 Sep; 40(5):473-5. PubMed ID: 14579716 [No Abstract] [Full Text] [Related]
14. Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease. Lannfelt L; Pettersson FE; Nilsson LN Nutr Rev; 2010 Dec; 68 Suppl 2():S128-34. PubMed ID: 21091946 [TBL] [Abstract][Full Text] [Related]
19. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Li Y; Liu Y; Wang Z; Jiang Y Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611 [TBL] [Abstract][Full Text] [Related]
20. [Advances in anti-beta antibody treatment of Alzheimer's disease]. Zhang JH; Liang P Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):633-5. PubMed ID: 18070457 [No Abstract] [Full Text] [Related] [Next] [New Search]